Polyphor Ltd and Axxam SpA Announce Ion Channel Collaboration
News Apr 13, 2010
Polyphor Ltd and Axxam SpA have announced a joint discovery agreement with a synergistic combination of their discovery platforms.
Under the terms of the collaboration the two companies will work together to discover and develop innovative drug candidates for selected therapeutic areas such as pain, inflammation, and metabolic disorders.
Axxam will apply its expertise and outstanding Hit Discovery platforms and capabilities, and Polyphor will provide its unique, proprietary PEM finder® library for screening together with its expertise in medicinal chemistry, drug discovery and development. The collaboration comprises several discovery programs addressing attractive ion channel based targets.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Prostate- and Colon Cancer Targeted With Tapeworm DrugNews
Recently researchers found that a substance in medicine against parasites like Giardia and Tapeworms, acts like tailored medicine against prostate- and colon cancer.READ MORE
Engineering the Gut Microbiome with 'Good' Bacteria May Help Treat Crohn's DiseaseNews
Researchers have singled out a bacterial enzyme behind an imbalance in the gut microbiome linked to Crohn's disease. Replacement of the offending bacteria with "good" bacteria may offer an effective treatment approach.READ MORE